Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

Nat Rev Clin Oncol. 2024 Mar;21(3):171-172. doi: 10.1038/s41571-023-00854-y.

Pier Paolo M Berton Giachetti^{1

2}, Giuseppe Curigliano^{3

4}

¹ Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. giuseppe.curigliano@ieo.it.
⁴ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. giuseppe.curigliano@ieo.it.

No abstract available

MeSH terms